Skip to main content
Premium Trial:

Request an Annual Quote

Canada Invests C$3M in Metabolomics Instruments

NEW YORK (GenomeWeb) – The Canadian Government today announced an investment of C$3 million (US$2.4 million) towards instruments to help establish the Metabolomics Technology Demonstration Centre, in partnership with Genome Alberta and the University of Alberta.

The instruments, a 700 MHz nuclear magnetic resonance machine and a quadrupole time-of-flight mass spectrometer, will assist companies in the metabolomics sector translate biomarker-based tests from the lab into the clinic. Companies will test, validate, and assemble prototypes using the University of Alberta Metabolomics Innovation Centre's biomarker panels, to create more accurate and less invasive medical tests.

"The Metabolomics Technology Demonstration Centre will provide Canadian researchers with cutting edge infrastructure and technical expertise to support translation of innovative biomarker discoveries into real life applications," David Wishart, professor of biological and computing sciences at the University of Alberta, said in a statement.

The National Institute of Nanotechnology, Alberta Innovates Health Solutions, Metabolomics Technologies, and Genome Canada are also contributors towards this project.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.